Novel Chemistry Platform Services

Our product candidates, designed for targeting cancer, are derived from a novel chemistry platform and cell-based differential screening, which together define our discovery approach. Most are simple two-ring or three-ring structures that are built around a common core or signature element. Most kinase enzymes require the binding of adenosine triphosphate, or ATP, to function. Unlike most kinase inhibitors, our proprietary library includes molecules that do not compete with the ATP binding site of kinases, which we believe may provide a more selective way to inhibit these enzymes. The Onconova platform has yielded a broad pipeline of clinical products.